John Stanford kicks off the official relaunch of the Making Medicine Podcast with a deep dive into the "one big beautiful bill" that’s shaking up Washington. From major tax cuts to game-changing reforms like the Orphan Cures Act, this episode covers what’s in—and what’s not—in the sweeping legislation. What’s the real impact on biotech innovation, Medicaid, PBMs, and future drug pricing? John breaks it all down while teasing what’s ahead in upcoming episodes, including Trump’s proposed pharma tariffs and the evolving role of the FDA.
Do you think the Orphan Cures Act goes far enough?
How will these tax and policy shifts impact innovation in rare disease and biotech?
📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps:
0:00 Welcome to Making Medicine
0:18 Podcast relaunch and weekly content
1:00 One big beautiful bill becomes law
1:38 Tax cuts, deficit concerns, and social program impacts
2:55 How the bill affects biotech and venture capital
3:26 Orphan Cures Act and rare disease investment
4:20 Inflation Reduction Act reforms not included
4:40 PBM cuts left out of the bill
5:20 Victory on Most Favored Nations policy
6:24 What “pay for” means in DC speak
6:59 Industry spared from being a “pay for”
7:03 What’s coming next: tariffs, NIH cuts, FDA changes
7:45 Subscribe and stay updated
